Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 9,126 matching trials from the live ClinicalTrials.gov search.

Filters: Tampa, Florida Clear all

Conditions: Crohn's Disease
Interventions: Mirikizumab, Ustekinumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 1,158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 140
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more

Conditions: Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Chordoma, Desmoid-Type Fibromatosis, Metastatic Childhood Soft Tissue Sarcoma, Non-Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7, Untreated Childhood Rhabdomyosarcoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2023
U.S. locations: 214
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 149 more

Conditions: Neoplasm Related Pain (Acute) (Chronic)
Interventions: Sodium Bicarbonate (NaHCO3); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hydrocephalus, Normal Pressure
Interventions: ShuntCheck; Diagnostic Test
Lead sponsor: University of South Florida; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Schizophrenia
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more

Conditions: Gastrointestinal Neoplasm
Interventions: Sutent; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 32
States / cities: Duarte, California • Pasadena, California • San Francisco, California + 24 more

Conditions: Covid19
Interventions: Favipiravir, Placebo; Drug
Lead sponsor: Appili Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Pelham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more

Conditions: Brain and Central Nervous System Tumors
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: New Approaches to Brain Tumor Therapy Consortium; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Chronic Inducible Urticaria
Interventions: Oral EP262; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more

Conditions: HIV Infection, Infection, Human Immunodeficiency Virus
Interventions: Half-boosted Fosamprenavir, Full Boosted Fosamprenavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more

Conditions: Coronary Atherosclerosis
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 97
States / cities: Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more

Conditions: Dry Eye Disease, Sjögren Syndrome
Interventions: Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution; Drug
Lead sponsor: Sylentis, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 35 more

Conditions: Glioblastoma
Interventions: Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide); Device
Lead sponsor: GT Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 13 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 310
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more

Conditions: Sleep Apnea, Obstructive
Interventions: Genio System; Device
Lead sponsor: Nyxoah S.A.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 16
States / cities: Colorado Springs, Colorado • Boca Raton, Florida • Miami, Florida + 11 more

Conditions: Chronic Pain, Chronic Insomnia, Opioid Use
Interventions: CBT-I, Treatment as usual, Tapered Withdrawal; Behavioral · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 49
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 41 more

Conditions: Depressive Disorder, Major
Interventions: JNJ-89495120, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more

Conditions: Human Immunodeficiency Virus Type 1
Interventions: TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more

Conditions: Prostate Cancer
Interventions: Standard of Care; Other
Lead sponsor: Prostate Cancer Clinical Trials Consortium; Other
Eligibility: 21 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 48
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more

Conditions: Colorectal Cancer
Interventions: capecitabine, oxaliplatin, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 67
States / cities: Scottsdale, Arizona • Concord, California • Duarte, California + 46 more

Conditions: Moderate to Severe Chronic Plaque Psoriasis
Interventions: Alefacept; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 36
States / cities: Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more

Search by objective public record fields.

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Bicarbonate for Tumor Related Pain

Assessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

The Prevent Severe COVID-19 (PRESECO) Study

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

CRESTOR Athero Imaging Head to Head IVUS Study

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

GammaTile and Stupp in Newly Diagnosed GBM

Safety and Efficacy of Albiglutide in Type 2 Diabetes

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

Improving Sleep and Reducing Opioid Use in Individuals With Chronic Pain

Belimumab Assessment of Safety in SLE

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

Community Based Trial for AMEVIVE®